Open access

GP41 DIVERSITY IN ANTIRETROVIRAL THERAPY NAïVE AND EXPERIENCED HIV-1 SUBTYPE C-INFECTED PATIENTS IN BOTSWANA: IMPLICATIONS FOR ENFUVIRTIDE (T-20) USE
Dorcas Maruapula, Boitumelo Seraise, Kevin Einkauf, Amanda Reilly, Sikhulile Moyo, Terence Mohammed, Christopher Rowley, Rosemary Musonda, Joseph Makhema, Simani Gaseitsiwe

BMJ Global Health Feb 2017, 2 (Suppl 2) A39-A40; DOI: 10.1136/bmjgh-2016-000260.104
PREVALENCE OF ADVERSE DRUG REACTIONS AMONG HIV/AIDS PATIENTS ON HAART IN UNIVERSITY OF MAIDUGURI TEACHING HOSPITAL (UMTH), NIGERIA: A FOUR-YEAR RETROSPECTIVE STUDY
Peter Bassi, Wadzani Gashau, Klungel Olaf, Alexander Dodoo, Prosper Okonkwo, Phyllis Kanki

BMJ Global Health Feb 2017, 2 (Suppl 2) A39; DOI: 10.1136/bmjgh-2016-000260.103
RELATIONSHIP OF HIV-HBV CO-INFECTION WITH CD4 CELL COUNT AND ALANINE TRANSAMINASE LEVELS IN ANTI-RETROVIRAL THERAPY-NAïVE PATIENTS
Kalo Musukuma, Roma Chilengi, Rosalia Dambe, Benjamin Usadi, Michael Vinikoor

BMJ Global Health Feb 2017, 2 (Suppl 2) A40-A41; DOI: 10.1136/bmjgh-2016-000260.107
HEPATITIS B VIRUS CO-INFECTION IS ASSOCIATED WITH INCREASED ALL-CAUSE MORTALITY AMONG HIV-INFECTED ADULTS ON TENOFOVIR-DISOPROXIL-FUMARATE CONTAINING ANTIRETROVIRAL THERAPY IN LUSAKA, ZAMBIA
Michael Vinikoor, Roma Chilengi, Lloyd Mulenga, Callistus Kaayunga, Zude Zyambo, Mary-Ann Davies, Matthias Egger, Gilles Wandeler

BMJ Global Health Feb 2017, 2 (Suppl 2) A40; DOI: 10.1136/bmjgh-2016-000260.106
BASELINE BACTERIAL LOAD AND RIFAMPICIN EXPOSURE ARE ASSOCIATED TO CULTURE CONVERSION IN A TWO-MONTH STUDY OF TUBERCULOSIS
Nyanda Ntinginya, Anna Framhein, Stella Mpagama, Hadija Semvua, Gibson Kibiki, Leonard Maboko, Michael Hoelscher, Norbert Heinrich

BMJ Global Health Feb 2017, 2 (Suppl 2) A40; DOI: 10.1136/bmjgh-2016-000260.105
PREVALENCE AND PREDISPOSING FACTORS TO INTESTINAL PARASITIC INFECTIONS IN HIV/AIDS PATIENTS IN FAKO DIVISION OF CAMEROON
Dickson Nsagha

BMJ Global Health Feb 2017, 2 (Suppl 2) A41; DOI: 10.1136/bmjgh-2016-000260.109
CAN HIV TREATMENTS INFORM OTHER CONTEXTS? A TRIAL OF AN ADDITIONAL INDICATION FOR CO-TRIMOXAZOLE PROPHYLAXIS
Moses Ngari, Johnstone Thitiri, Laura Mwalekwa, Greg Fegan, James Berkley

BMJ Global Health Feb 2017, 2 (Suppl 2) A41; DOI: 10.1136/bmjgh-2016-000260.108
CRYPTOCOCCAL MENINGOENCEPHALITIS IN HIV-INFECTED PATIENTS IN MADAGASCAR: HIGH PREVALENCE AND LETHALITY AND THERAPEUTIC CHALLENGES
Rivo Rakotoarivelo, Mihaja Raberahona, Njary Randriamampionona, Rabezanahary Andriamihaja, Tahinamandranto Rasamoelina, Muriel Cornet, Mamy Jean De Dieu Randria, Thomas Benet, Philippe Vanhems, Mala Rakoto Andrianarivelo

BMJ Global Health Feb 2017, 2 (Suppl 2) A42-A43; DOI: 10.1136/bmjgh-2016-000260.112
IMPACT OF COMMUNITY TRACING ON HIV COHORT OUTCOMES IN URBAN ZAMBIA
Virginia Munamunungu, Carolyn Bolton, Alice Siyunda, Jacinta Shilimi, Roma Chilengi, Gilles Wandeler, Michael Vinikoor

BMJ Global Health Feb 2017, 2 (Suppl 2) A42; DOI: 10.1136/bmjgh-2016-000260.110
PREDICTORS OF RETENTION IN CARE OF HIV-INFECTED ADULTS IN TIGRAY, ETHIOPIA: A PROSPECTIVE COHORT STUDY
Raffaella Bucciardini, Vincenzo Fragola, Teshome Abegaz, Stefano Lucattini, Atakilt Halifom, Eskedar Tadesse, Micheal Berhe, Katherina Pugliese, Paola De Castro, Roberta Terlizzi, Luca Fucili, Massimiliano Di Gregorio, Marco Mirra, Teame Zegeye, Andrea Binelli, Stefano Vella, Loko Abraham, Hagos Godefay

BMJ Global Health Feb 2017, 2 (Suppl 2) A42; DOI: 10.1136/bmjgh-2016-000260.111

Main menu

Open access

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Open access

Pages